Skip to main content
Quest Diagnostics

Clinical Utility of Plasma Aβ42/40 Ratio by LC-MS/MS in Alzheimer’s Disease Assessment

Clinical Utility of Plasma Aβ42/40 Ratio by LC-MS/MS in Alzheimer’s Disease Assessment

Authors: Weber DM, Taylor SW, Lagier RJ, Kim JC, Goldman SM, Clarke NJ, Vaillancourt DE, Duara R, McFarland KN, Wang W-E, Golde TE, Racke MK

Citation: Front Neurol. 2024;15:1364658. doi:10.3389/fneur.2024.1364658

Specialties: Neurology

Download key summary

Related content

Conference Presentation
A New LC-MS/MS Assay for the Quantification of Aβ40 and Aβ42 in Plasma: Validation and Clinical Performance
Conference Presentation
Associations of Beta-amyloid and Alzheimer’s Disease Risk With Patient Age in Over 2,000 Plasma Specimens Analyzed by LC-MS/MS
Audio Podcast
Patient-minded Neurology
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
Publication
The small HDL particle hypothesis of Alzheimer's disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.